Managing gout

This is the lay version of the EULAR recommendations for the management of people with gout. The original publication can be downloaded from the EULAR website: www.eular.org. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42. doi:10.1136/annrheumdis-2016-209707 Introduction EULAR recommendations give advice to doctors, nurses and […]

Read More…

Risk of side effects increased in people from certain racial or ethnic backgrounds

Allopurinol should be used with caution in people with Black, Asian, or Native Hawaiian/Pacific Islander heritage. Introduction Gout is a very common condition. It is caused by deposits of crystals of a substance called uric acid (also known as urate) in the joints, which leads to inflammation. Periods of time when you have gout symptoms […]

Read More…

Treat-to-target could be a reality in gout

Targeting urate levels could help to improve care for people with gout. INTRODUCTION Gout is a very common condition, affecting up to 2% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in the joints. It is caused by deposits of crystals […]

Read More…

Gout may be associated with vascular events such as stroke or heart attacks, particularly in women

Patients with gout – especially women – may be more likely to suffer from vascular diseases such as stroke, heart attack, angina or heart disease. INTRODUCTION Gout is a very common condition, affecting 2.5% of the population in the UK. The symptoms tend to flare every so often, developing over a few hours and causing […]

Read More…